xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">
http://news.bbc.co.uk/hi/english/health/newsid_1818000/1818065.stm
Wednesday, 13 February, 2002, 19:55 GMT
New TB
vaccines 'in pipeline'

The
TB bacterium is becoming resistant to drugs
Scientists
may have found a way to improve the effectiveness of the vaccination which
protects humans against TB infection.
TB is caused by a bacterium that spreads
through the air and infects the lungs.
The Bacillus Calmette-Guerin or BCG vaccine
has been used for nearly 50 years and gives 70% protection, but doctors believe
a better vaccine is needed.
|

BCG is not as effective as more modern vaccines like MMR,
which gives 99% protection after two doses

|
|
Public Health Service Laboratory spokesman
|
BCG is a weakened strain of Mycobacterium
bovis, the bacterium that gives cattle thieir version of TB.
While the vaccine has saved millions of
lives, it still fails to prevent TB in as many as 80% of the people who get the
shots.
"Now we have a good explanation for the
failure of BCG and have found a way round the problem," said Peter
Andersen, head of the research team which made the discovery in Denmark.
He and his colleagues believe the failure of
BCG is due to weaker relatives of Mycobacterium tuberculosis, the bug that
causes TB in people.
These strains accidentally sabotage the
vaccine by getting to people first, via water and food in hot countries.
BCG immunity
Mr Andersen said: "Essentially they
immunise people against BCG."
In an article in New Scientist, Mr Andersen
says they prevent the BCG vaccine from multiplying inside the body and do not
trigger enough immunity to protect against TB.
This theory explains why BCG will protect
infants if they are injected just after birth, before environmental
mycobacteria can get in the way.
Mr Andersen proved the link by infecting mice
with three related strains of mycobacteria, all of them isolated from patients
and soil in parts of Malawi, where BCG does not work.
In each case, subsequent BCG shots failed to
stop the mice getting TB.
Paul Fine, professor of communicable disease
epidemiology at the London School of Hygiene and Tropical Medicine, says the
paper "comes up with the best evidence yet" that prior exposure to
related bacteria nullifies BCG.
New vaccines
A spokesman for the Public Health Laboratory
Service said the BCG vaccine has had a powerful effect on TB.
He said: "To suggest it is ineffective
would be misleading.
"BCG is not as effective as more modern
vaccines like MMR, which gives 99% protection after two doses.
"But it's a tool in the armoury, but not
the only device to control the disease.
"We need early diagnosis, rapid
treatment and good screening facilities."
There is good news that new vaccines made
from fragments of dead TB bacteria did protect the pre-infected mice from TB.
Unlike live TB vaccines, these do not need to
multiply in the body to be effective.
Mr Andersen said: "There are many such
vaccines in the pipeline."
Only one has so far reached the stage of
clinical trials.
It is now hoped new vaccines might provide
immunity for adolescents whose BCG protection has either worn off or never took
hold in the first place.
There was a record rise in new TB cases last
year in the UK, with almost 7,000 people diagnosed with the condition.
ALL
INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR
GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE
KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED
AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO
VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU
ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.